PF-514273 is a drug developed by
Pfizer, which acts as an extremely selective
antagonist for the
CB1receptor, with approximately 10,000x selectivity over the closely related
CB2 receptor. This very high selectivity makes it useful for scientific research into these receptors, as many commonly used
cannabinoid receptor antagonists also block the CB2 receptor to some extent.[1]
References
^Dow RL, Carpino PA, Hadcock JR, Black SC, Iredale PA, DaSilva-Jardine P, et al. (May 2009). "Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6,7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273), a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity". Journal of Medicinal Chemistry. 52 (9): 2652–5.
doi:
10.1021/jm900255t.
PMID19351113.